Richard Rosen, MD
The objective of this trial will be to explore the safety and efficacy of intravitreous injections of Macugen® (pegaptanib sodium) when given every 6 weeks for 48 weeks in subjects with exudative maculopathy who, after previous treatment regimen, have improved based upon clinical and anatomical (OCT) findings as determined by the investigator.
MACUGEN® (Pegaptanib Sodium) treatment given every 6 weeks for up to 2 years has been shown to significantly reduce the risk of moderate vision loss in patients with all types of wet AMD. Data suggests that patients who had early wet AMD and were treated with MACUGEN® had improved vision outcomes than those who started treatment later.
These kinds of results highlight the importance of beginning treatment before wet AMD becomes advanced and routine activities become difficult.
For more information: